Concepedia

Author

Cédric Barrière

Sanofi (France)

Also Known As

C. Barrière, Cedric Barriere, Cédric Barrière, Cédric Barrière

39

Publications

1.9K

Citations

8

H-Index

18

Concepts

All Affiliations

Sanofi (France)Spanish National Cancer Research CentreUniversité de BordeauxInstitut Curie
CB

About

Cédric Barrière is an author at Sanofi (France) specializing in medicine, cell division, and cellular physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

1.2K

2

Natural Sciences

1

1

90

3

Biochemistry

1

1

90

4

Cell Biology

1

1

1.1K

5

Cellular Physiology

1

1

1.1K

Cédric Barrière

×

8

Publications

1.9K

Citations

8

H-Index

YearCitations

Cdk1 is sufficient to drive the mammalian cell cycle

David Santamarı́a, Cédric Barrière, Antonio Cerqueira,

Nature

2007

1.1K

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Shaomeng Wang, Wei Sun, Yujun Zhao,

Cancer Research

2014

335

Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut

Maïa Chanrion, Inna Kuperstein, Cédric Barrière,

Nature Communications

2014

131

Mice thrive without Cdk4 and Cdk2

Cédric Barrière, David Santamarı́a, Antonio Cerqueira,

Molecular Oncology

2007

123

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma

Kate Lynn J. Bill, Jeannine Garnett, Isabelle Meaux,

Clinical Cancer Research

2015

106

Discovery of (2<i>S</i>)-8-[(3<i>R</i>)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2<i>H</i>-pyrimido[1,2-<i>a</i>]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors

Benoit Pasquier, Youssef El‐Ahmad, Bruno Filoche-Rommé,

Journal of Medicinal Chemistry

2014

90

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Minjee Kim, J. Daniel, David Calligaris,

Molecular Cancer Therapeutics

2018

40

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

Hélène Bonnevaux, S. Guérif, Jana D. Albrecht,

OncoImmunology

2021

14

Page 1